Why Stack Retatrutide and Cagrilintide?
Retatrutide and cagrilintide work through completely different receptor systems. Retatrutide activates GIP, GLP-1, and glucagon receptors — the incretin and metabolic axis. Cagrilintide is an amylin analog, mimicking a hormone secreted alongside insulin that primarily slows gastric emptying and suppresses appetite through the area postrema in the brainstem. Because the drugs target different biological pathways, their effects may be additive. The theory is that adding a separate satiety signal through the amylin pathway could enhance the weight loss achieved by retatrutide alone. No clinical data exists on this specific combination.
Suggested Dosing Protocol
Based on the Phase 2 clinical data for each drug individually, a cautious stacking protocol would start retatrutide at 2 mg weekly and titrate up to 4-8 mg over 8 weeks before introducing cagrilintide at a low dose. Cagrilintide has been studied at doses of 0.3 mg to 4.5 mg weekly in clinical trials. A starting dose of 0.3-0.6 mg weekly, titrated gradually, is the most conservative approach. Combining doses that each cause nausea independently requires careful titration to avoid intolerable gastrointestinal side effects. Users on Reddit report that the combination is effective but that the nausea can be challenging during the first few weeks.
Risks and Considerations
The primary risk of stacking retatrutide and cagrilintide is additive gastrointestinal side effects. Both drugs slow gastric emptying, and together they may cause more nausea, vomiting, and constipation than either drug alone. The heart rate increase from retatrutide’s glucagon receptor activation is unlikely to be affected by cagrilintide, which does not have chronotropic effects. The lack of clinical data means that optimal dosing, long-term safety, and drug interactions are unknown. Anyone considering this stack should start at the lowest possible doses and increase slowly, monitoring for side effects carefully.
Leave a Reply